Search

Your search keyword '"Gallia A"' showing total 3,114 results
Start Over Author "Gallia A"
3,114 results on '"Gallia A"'

151. Reexamining the Role of Postoperative ICU Admission for Patients Undergoing Elective Craniotomy: A Systematic Review*

Author

Tej D, Azad, Pavan P, Shah, Nivedha V, Kannapadi, Jordina, Rincon-Torroella, Yuanxuan, Xia, Lydia J, Bernhardt, Landon J, Hansen, Joshua, Materi, Divyaansh, Raj, Christopher M, Jackson, Debraj, Mukherjee, Gary L, Gallia, Jon, Weingart, Jose I, Suarez, Henry, Brem, and Chetan, Bettegowda

Subjects
Postoperative Care, Intensive Care Units, Postoperative Complications, Elective Surgical Procedures, Humans, Postoperative Period, Length of Stay, Critical Care and Intensive Care Medicine, Craniotomy
Abstract

The standard-of-care for postoperative care following elective craniotomy has historically been ICU admission. However, recent literature interrogating complications and interventions during this postoperative ICU stay suggests that all patients may not require this level of care. Thus, hospitals began implementing non-ICU postoperative care pathways for elective craniotomy. This systematic review aims to summarize and evaluate the existing literature regarding outcomes and costs for patients receiving non-ICU care after elective craniotomy.A systematic review of the PubMed database was performed following PRISMA guidelines from database inception to August 2021.Included studies were published in peer-reviewed journals, in English, and described outcomes for patients undergoing elective craniotomies without postoperative ICU care.Data regarding study design, patient characteristics, and postoperative care pathways were extracted independently by two authors. Quality and risk of bias were evaluated using the Oxford Centre for Evidence-Based Medicine Levels of Evidence tool and Risk Of Bias In Non-Randomized Studies-of Interventions tool, respectively.In total, 1,131 unique articles were identified through the database search, with 27 meeting inclusion criteria. Included articles were published from 2001 to 2021 and included non-ICU inpatient care and same-day discharge pathways. Overall, the studies demonstrated that postoperative non-ICU care for elective craniotomies led to length of stay reduction ranging from 6 hours to 4 days and notable cost reductions. Across 13 studies, 53 of the 2,469 patients (2.1%) intended for postoperative management in a non-ICU setting required subsequent care escalation.Overall, these studies suggest that non-ICU care pathways for appropriately selected postcraniotomy patients may represent a meaningful opportunity to improve care value. However, included studies varied greatly in patient selection, postoperative care protocol, and outcomes reporting. Standardization and multi-institutional collaboration are needed to draw definitive conclusions regarding non-ICU postoperative care for elective craniotomy.

Published
2022
Full Text
View/download PDF

153. Concurrent heterozygous Von-Hippel–Lindau and transmembrane-protein-127 gene mutation causing an erythropoietin-secreting pheochromocytoma in a normotensive patient with severe erythrocytosis

Author

Negro, Aurelio, Graiani, Gallia, Nicoli, Davide, Farnetti, Enrico, Casali, Bruno, Verzicco, Ignazio, Tedeschi, Stefano, Ghirarduzzi, Angelo, Cannone, Valentina, Marco, Loredana D.E., Filice, Angela, Gemelli, Giuseppe, Giunta, Alessandro, and Cabassi, Aderville

Published
2020
Full Text
View/download PDF

156. Characterization of Cancer Stem Cells in Olfactory Neuroblastoma Identifies Increased PD-L1 Expression.

Author

Ramolia, Shivani, Larkin, Riley, Robbins, Yvette, Lopez, Diana, Lassoued, Wiem, Gulley, James, Gallia, Gary, Allen, Clint, and London, Nyall

Subjects
CANCER stem cells, OLFACTORY receptors, PROGRAMMED death-ligand 1, NEUROBLASTOMA
Abstract

This article discusses the characterization of cancer stem cells (CSCs) in olfactory neuroblastoma (ONB), a rare malignant neoplasm. The study aimed to identify the density of CSCs and PD-L1 expression in ONB using immunofluorescence. The results showed that CSCs were present in ONB, but they were uncommon and did not correlate with grade, stage, or recurrence. However, a significant number of CSCs expressed PD-L1, suggesting a potential immunotherapy strategy for ONB by targeting this cell population through PD-1/PD-L1 immune checkpoint blockade. [Extracted from the article]

Published
2024
Full Text
View/download PDF

157. Robust Optimization of a Thermal Anti-Ice Protection System in Uncertain Cloud Conditions.

Author

Gallia, Mariachiara, Gutiérrez, Bárbara Arizmendi, Gori, Giulio, Guardone, Alberto, and Congedo, Pietro M.

Abstract

This paper presents a framework for the robust optimization of the heat flux distribution for an anti-ice electrothermal ice protection system under uncertain conditions. The considered uncertainty regards a lack of knowledge concerning the characteristics of the cloud, i.e., the liquid water content and the median volume diameter of water droplets, and the accuracy of measuring devices, i.e., the static temperature probe. Uncertain parameters are modeled as random variables, and two sets of bounds are investigated. A forward uncertainty propagation analysis is carried out using a Monte Carlo approach exploiting a surrogate models. The optimization framework relies on a gradient-free algorithm (mesh adaptive direct search), and two different objective functions are considered, namely, the 95 quantile of the freezing mass rate and the statistical frequency of the fully evaporative operating regime. The framework is applied to a reference test case, revealing a potential to improve the heat flux distribution of the baseline design. A new heat flux distribution is proposed, and it presents a more efficient use of the thermal power, increasing flight safety even at nonnominal environmental conditions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

160. Supplementary Table 1 from NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches

Author

Baia, Gilson S., primary, Caballero, Otavia L., primary, Ho, Janelle S.Y., primary, Zhao, Qi, primary, Cohen, Tzeela, primary, Binder, Zev A., primary, Salmasi, Vafi, primary, Gallia, Gary L., primary, Quinones-Hinojosa, Alfredo, primary, Olivi, Alessandro, primary, Brem, Henry, primary, Burger, Peter, primary, Strausberg, Robert L., primary, Simpson, Andrew J.G., primary, Eberhart, Charles G., primary, and Riggins, Gregory J., primary

Published
2023
Full Text
View/download PDF

161. Supplementary Methods from NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches

Author

Baia, Gilson S., primary, Caballero, Otavia L., primary, Ho, Janelle S.Y., primary, Zhao, Qi, primary, Cohen, Tzeela, primary, Binder, Zev A., primary, Salmasi, Vafi, primary, Gallia, Gary L., primary, Quinones-Hinojosa, Alfredo, primary, Olivi, Alessandro, primary, Brem, Henry, primary, Burger, Peter, primary, Strausberg, Robert L., primary, Simpson, Andrew J.G., primary, Eberhart, Charles G., primary, and Riggins, Gregory J., primary

Published
2023
Full Text
View/download PDF

162. Supplementary Table 2 from NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches

Author

Baia, Gilson S., primary, Caballero, Otavia L., primary, Ho, Janelle S.Y., primary, Zhao, Qi, primary, Cohen, Tzeela, primary, Binder, Zev A., primary, Salmasi, Vafi, primary, Gallia, Gary L., primary, Quinones-Hinojosa, Alfredo, primary, Olivi, Alessandro, primary, Brem, Henry, primary, Burger, Peter, primary, Strausberg, Robert L., primary, Simpson, Andrew J.G., primary, Eberhart, Charles G., primary, and Riggins, Gregory J., primary

Published
2023
Full Text
View/download PDF

163. Supplementary Figures 1 - 5 from NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches

Author

Baia, Gilson S., primary, Caballero, Otavia L., primary, Ho, Janelle S.Y., primary, Zhao, Qi, primary, Cohen, Tzeela, primary, Binder, Zev A., primary, Salmasi, Vafi, primary, Gallia, Gary L., primary, Quinones-Hinojosa, Alfredo, primary, Olivi, Alessandro, primary, Brem, Henry, primary, Burger, Peter, primary, Strausberg, Robert L., primary, Simpson, Andrew J.G., primary, Eberhart, Charles G., primary, and Riggins, Gregory J., primary

Published
2023
Full Text
View/download PDF

164. Supplementary Table 3 from NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches

Author

Baia, Gilson S., primary, Caballero, Otavia L., primary, Ho, Janelle S.Y., primary, Zhao, Qi, primary, Cohen, Tzeela, primary, Binder, Zev A., primary, Salmasi, Vafi, primary, Gallia, Gary L., primary, Quinones-Hinojosa, Alfredo, primary, Olivi, Alessandro, primary, Brem, Henry, primary, Burger, Peter, primary, Strausberg, Robert L., primary, Simpson, Andrew J.G., primary, Eberhart, Charles G., primary, and Riggins, Gregory J., primary

Published
2023
Full Text
View/download PDF

165. Data from NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches

Author

Baia, Gilson S., primary, Caballero, Otavia L., primary, Ho, Janelle S.Y., primary, Zhao, Qi, primary, Cohen, Tzeela, primary, Binder, Zev A., primary, Salmasi, Vafi, primary, Gallia, Gary L., primary, Quinones-Hinojosa, Alfredo, primary, Olivi, Alessandro, primary, Brem, Henry, primary, Burger, Peter, primary, Strausberg, Robert L., primary, Simpson, Andrew J.G., primary, Eberhart, Charles G., primary, and Riggins, Gregory J., primary

Published
2023
Full Text
View/download PDF

166. Supplementary Figure Legend from NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches

Author

Baia, Gilson S., primary, Caballero, Otavia L., primary, Ho, Janelle S.Y., primary, Zhao, Qi, primary, Cohen, Tzeela, primary, Binder, Zev A., primary, Salmasi, Vafi, primary, Gallia, Gary L., primary, Quinones-Hinojosa, Alfredo, primary, Olivi, Alessandro, primary, Brem, Henry, primary, Burger, Peter, primary, Strausberg, Robert L., primary, Simpson, Andrew J.G., primary, Eberhart, Charles G., primary, and Riggins, Gregory J., primary

Published
2023
Full Text
View/download PDF

167. 772 Re-examining the Role of Post-Operative ICU Admission for Patients Undergoing Elective Craniotomy: A Systematic Review

Author

Azad, Tej D., primary, Shah, Pavan P., additional, Kannapadi, Nivedha, additional, Rincon Torroella, Jordina N., additional, Xia, Yuanxuan, additional, Bernhardt, Lydia, additional, Hansen, Landon John, additional, Materi, Joshua, additional, Raj, Divyaansh, additional, Jackson, Christopher Mitchell, additional, Mukherjee, Raj, additional, Gallia, Gary L., additional, Weingart, Jon, additional, Suarez, Jose, additional, Brem, Henry, additional, and Bettegowda, Chetan, additional

Published
2023
Full Text
View/download PDF

169. Titles and captions for supplementary tables and figures from First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Author

Sarker, Debashis, primary, Ang, Joo Ern, primary, Baird, Richard, primary, Kristeleit, Rebecca, primary, Shah, Krunal, primary, Moreno, Victor, primary, Clarke, Paul A., primary, Raynaud, Florence I., primary, Levy, Gallia, primary, Ware, Joseph A., primary, Mazina, Kathryn, primary, Lin, Ray, primary, Wu, Jenny, primary, Fredrickson, Jill, primary, Spoerke, Jill M., primary, Lackner, Mark R., primary, Yan, Yibing, primary, Friedman, Lori S., primary, Kaye, Stan B., primary, Derynck, Mika K., primary, Workman, Paul, primary, and de Bono, Johann S., primary

Published
2023
Full Text
View/download PDF

170. Supplementary Figure 3 from First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Author

Sarker, Debashis, primary, Ang, Joo Ern, primary, Baird, Richard, primary, Kristeleit, Rebecca, primary, Shah, Krunal, primary, Moreno, Victor, primary, Clarke, Paul A., primary, Raynaud, Florence I., primary, Levy, Gallia, primary, Ware, Joseph A., primary, Mazina, Kathryn, primary, Lin, Ray, primary, Wu, Jenny, primary, Fredrickson, Jill, primary, Spoerke, Jill M., primary, Lackner, Mark R., primary, Yan, Yibing, primary, Friedman, Lori S., primary, Kaye, Stan B., primary, Derynck, Mika K., primary, Workman, Paul, primary, and de Bono, Johann S., primary

Published
2023
Full Text
View/download PDF

173. Supplementary Table 1 from First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Author

Sarker, Debashis, primary, Ang, Joo Ern, primary, Baird, Richard, primary, Kristeleit, Rebecca, primary, Shah, Krunal, primary, Moreno, Victor, primary, Clarke, Paul A., primary, Raynaud, Florence I., primary, Levy, Gallia, primary, Ware, Joseph A., primary, Mazina, Kathryn, primary, Lin, Ray, primary, Wu, Jenny, primary, Fredrickson, Jill, primary, Spoerke, Jill M., primary, Lackner, Mark R., primary, Yan, Yibing, primary, Friedman, Lori S., primary, Kaye, Stan B., primary, Derynck, Mika K., primary, Workman, Paul, primary, and de Bono, Johann S., primary

Published
2023
Full Text
View/download PDF

176. Supplementary Figure 2 from First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Author

Sarker, Debashis, primary, Ang, Joo Ern, primary, Baird, Richard, primary, Kristeleit, Rebecca, primary, Shah, Krunal, primary, Moreno, Victor, primary, Clarke, Paul A., primary, Raynaud, Florence I., primary, Levy, Gallia, primary, Ware, Joseph A., primary, Mazina, Kathryn, primary, Lin, Ray, primary, Wu, Jenny, primary, Fredrickson, Jill, primary, Spoerke, Jill M., primary, Lackner, Mark R., primary, Yan, Yibing, primary, Friedman, Lori S., primary, Kaye, Stan B., primary, Derynck, Mika K., primary, Workman, Paul, primary, and de Bono, Johann S., primary

Published
2023
Full Text
View/download PDF

177. Supplementary Table 2 from First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Author

Sarker, Debashis, primary, Ang, Joo Ern, primary, Baird, Richard, primary, Kristeleit, Rebecca, primary, Shah, Krunal, primary, Moreno, Victor, primary, Clarke, Paul A., primary, Raynaud, Florence I., primary, Levy, Gallia, primary, Ware, Joseph A., primary, Mazina, Kathryn, primary, Lin, Ray, primary, Wu, Jenny, primary, Fredrickson, Jill, primary, Spoerke, Jill M., primary, Lackner, Mark R., primary, Yan, Yibing, primary, Friedman, Lori S., primary, Kaye, Stan B., primary, Derynck, Mika K., primary, Workman, Paul, primary, and de Bono, Johann S., primary

Published
2023
Full Text
View/download PDF

178. Supplementary Figure 1 from First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Author

Sarker, Debashis, primary, Ang, Joo Ern, primary, Baird, Richard, primary, Kristeleit, Rebecca, primary, Shah, Krunal, primary, Moreno, Victor, primary, Clarke, Paul A., primary, Raynaud, Florence I., primary, Levy, Gallia, primary, Ware, Joseph A., primary, Mazina, Kathryn, primary, Lin, Ray, primary, Wu, Jenny, primary, Fredrickson, Jill, primary, Spoerke, Jill M., primary, Lackner, Mark R., primary, Yan, Yibing, primary, Friedman, Lori S., primary, Kaye, Stan B., primary, Derynck, Mika K., primary, Workman, Paul, primary, and de Bono, Johann S., primary

Published
2023
Full Text
View/download PDF

179. Supplementary Figure 4 from First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Author

Sarker, Debashis, primary, Ang, Joo Ern, primary, Baird, Richard, primary, Kristeleit, Rebecca, primary, Shah, Krunal, primary, Moreno, Victor, primary, Clarke, Paul A., primary, Raynaud, Florence I., primary, Levy, Gallia, primary, Ware, Joseph A., primary, Mazina, Kathryn, primary, Lin, Ray, primary, Wu, Jenny, primary, Fredrickson, Jill, primary, Spoerke, Jill M., primary, Lackner, Mark R., primary, Yan, Yibing, primary, Friedman, Lori S., primary, Kaye, Stan B., primary, Derynck, Mika K., primary, Workman, Paul, primary, and de Bono, Johann S., primary

Published
2023
Full Text
View/download PDF

182. Data Supplement from TLR9 Is Critical for Glioma Stem Cell Maintenance and Targeting

Author

Herrmann, Andreas, primary, Cherryholmes, Gregory, primary, Schroeder, Anne, primary, Phallen, Jillian, primary, Alizadeh, Darya, primary, Xin, Hong, primary, Wang, Tianyi, primary, Lee, Heehyoung, primary, Lahtz, Christoph, primary, Swiderski, Piotr, primary, Armstrong, Brian, primary, Kowolik, Claudia, primary, Gallia, Gary L., primary, Lim, Michael, primary, Brown, Christine, primary, Badie, Behnam, primary, Forman, Stephen, primary, Kortylewski, Marcin, primary, Jove, Richard, primary, and Yu, Hua, primary

Published
2023
Full Text
View/download PDF

185. Data from TLR9 Is Critical for Glioma Stem Cell Maintenance and Targeting

Author

Herrmann, Andreas, primary, Cherryholmes, Gregory, primary, Schroeder, Anne, primary, Phallen, Jillian, primary, Alizadeh, Darya, primary, Xin, Hong, primary, Wang, Tianyi, primary, Lee, Heehyoung, primary, Lahtz, Christoph, primary, Swiderski, Piotr, primary, Armstrong, Brian, primary, Kowolik, Claudia, primary, Gallia, Gary L., primary, Lim, Michael, primary, Brown, Christine, primary, Badie, Behnam, primary, Forman, Stephen, primary, Kortylewski, Marcin, primary, Jove, Richard, primary, and Yu, Hua, primary

Published
2023
Full Text
View/download PDF

194. Novel Predictive Models for High-Value Care Outcomes Following Glioblastoma Resection

Author

Sumil K. Nair, Sachiv Chakravarti, Adrian E. Jimenez, David Botros, Ian Chiu, Hanan Akbari, Keiko Fox, Christopher Jackson, Gary Gallia, Chetan Bettegowda, Jon Weingart, and Debraj Mukherjee

Subjects
Surgeons, Humans, Surgery, Neurology (clinical), Karnofsky Performance Status, Middle Aged, Glioblastoma, Hospital Charges, Retrospective Studies
Abstract

Treating patients with glioblastoma (GBM) requires extensive medical infrastructure. Individualized risk assessment for extended length of stay (LOS), nonroutine discharge disposition, and increased total hospital charges is critical to optimize delivery of care. Our study sought to develop predictive models identifying independent risk factors for these outcomes.We retrospectively reviewed patients undergoing GBM resection at our institution between January 2017 and September 2020. Extended LOS and elevated hospital charges were defined as values in the upper quartile of the cohort. Nonroutine discharge was defined as any disposition other than to home. Multivariate models for each outcome included covariates demonstrating P ≤ 0.10 on bivariate analysis.We identified 265 patients undergoing GBM resection, with an average age of 58.2 years. 24.5% of patients experienced extended LOS, 22.6% underwent nonroutine discharge, and 24.9% incurred elevated total hospital charges. Decreasing Karnofsky Performance Status (KPS) (P = 0.004), increasing modified 5-factor frailty (mFI-5) index (P = 0.012), lower surgeon experience (P = 0.005), emergent surgery (P0.0001), and larger tumor volume (P0.0001) predicted extended LOS. Independent predictors of nonroutine discharge included older age (P = 0.02), decreasing KPS (P0.0001), and emergent surgery (P = 0.048). Nonprivate insurance (P = 0.011), decreasing KPS (P = 0.029), emergent surgery (P0.0001), and larger tumor volume (P = 0.004) predicted elevated hospital charges. These models were incorporated into an open-access online calculator (https://neurooncsurgery3.shinyapps.io/gbm_calculator/).Several factors were independent predictors for at least 1 high-value care outcome, with lower KPS and emergent admission associated with each outcome. These models and our calculator may help clinicians provide individualized postoperative risk assessment to glioblastoma patients.

Published
2022
Full Text
View/download PDF

195. Supplementary Table 2 from NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches

Author

Gregory J. Riggins, Charles G. Eberhart, Andrew J.G. Simpson, Robert L. Strausberg, Peter Burger, Henry Brem, Alessandro Olivi, Alfredo Quinones-Hinojosa, Gary L. Gallia, Vafi Salmasi, Zev A. Binder, Tzeela Cohen, Qi Zhao, Janelle S.Y. Ho, Otavia L. Caballero, and Gilson S. Baia

Abstract

XLSX file - 22K, Clinical Variables of Meningioma Cases and Summary of the Immunohistochemistry Results Stratified by Grade.

Published
2023
Full Text
View/download PDF

196. Supplementary Table 1 from NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches

Author

Gregory J. Riggins, Charles G. Eberhart, Andrew J.G. Simpson, Robert L. Strausberg, Peter Burger, Henry Brem, Alessandro Olivi, Alfredo Quinones-Hinojosa, Gary L. Gallia, Vafi Salmasi, Zev A. Binder, Tzeela Cohen, Qi Zhao, Janelle S.Y. Ho, Otavia L. Caballero, and Gilson S. Baia

Abstract

XLSX file - 45K, Primer Sequences for PCR Amplification of Cancer/Testis Genes.

Published
2023
Full Text
View/download PDF

198. Supplementary Figures 1 - 5 from NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches

Author

Gregory J. Riggins, Charles G. Eberhart, Andrew J.G. Simpson, Robert L. Strausberg, Peter Burger, Henry Brem, Alessandro Olivi, Alfredo Quinones-Hinojosa, Gary L. Gallia, Vafi Salmasi, Zev A. Binder, Tzeela Cohen, Qi Zhao, Janelle S.Y. Ho, Otavia L. Caballero, and Gilson S. Baia

Abstract

PDF file - 849K, Supplementary Figure 1 - Expression of Cancer/Testis Genes in Meningioma. Supplementary Figure 2 - NY-ESO-1 and MAGEA3 Expression in Testis. Supplementary Figure 3 - MAGEA3 Expression in Meningioma. Supplementary Figure 4 - Immunohistochemistry of Human Lymphocytes in Tonsil. Supplementary Figure 5 - Correlation of NY-ESO-1 expression and patient outcome.

Published
2023
Full Text
View/download PDF

200. Supplementary Table 3 from NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches

Author

Gregory J. Riggins, Charles G. Eberhart, Andrew J.G. Simpson, Robert L. Strausberg, Peter Burger, Henry Brem, Alessandro Olivi, Alfredo Quinones-Hinojosa, Gary L. Gallia, Vafi Salmasi, Zev A. Binder, Tzeela Cohen, Qi Zhao, Janelle S.Y. Ho, Otavia L. Caballero, and Gilson S. Baia

Abstract

XLSX file - 26K, Analysis for Reactivity to NY-ESO-1 Protein by ELISA in Meningioma Serum Samples.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results